Imidazotriazines and imidazopyrimidines as kinase inhibitors

US8461330B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Jincong Zhuo · Boothwyn, US
• Meizhong Xu · Hockessin, US
• Chunhong He · Boothwyn, US
• Colin Zhang · Ambler, US
• Ding-Quan Qian · Newark, US
• David M. Burns · Woodbury, US
• Yun-Long Li · Chadds Ford, US
• Brian W. Metcalf · Moraga, US
• Wenqing Yao · Kennett Square, US

Key dates

• Filing date: Jun 10, 2010
• Grant date: Jun 11, 2013
• Expiry date: Dec 3, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.